药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Rolitetracycline
Pipemidic acid
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Pipemidic acid.
Rolitetracycline
Rufloxacin
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Rufloxacin.
Rolitetracycline
Piromidic acid
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Piromidic acid.
Rolitetracycline
Acetyldigoxin
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Acetyldigoxin.
Rolitetracycline
Lorajmine
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Lorajmine.
Rolitetracycline
Oxolinic acid
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Oxolinic acid.
Rolitetracycline
Prajmaline
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Prajmaline.
Rolitetracycline
Cibenzoline
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Cibenzoline.
Rolitetracycline
Cicletanine
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Cicletanine.
Rolitetracycline
Pilsicainide
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Pilsicainide.
Rolitetracycline
Givinostat
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Givinostat.
Rolitetracycline
Temefos
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Temefos.
Rolitetracycline
Prulifloxacin
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Prulifloxacin.
Rolitetracycline
CUDC-907
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with CUDC-907.
Rolitetracycline
Anisodamine
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Anisodamine.
Rolitetracycline
Pazufloxacin
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Pazufloxacin.
Rolitetracycline
Bilastine
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Bilastine.
Rolitetracycline
Difloxacin
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Difloxacin.
Rolitetracycline
Sarafloxacin
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Sarafloxacin.
Rolitetracycline
Phosmet
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Phosmet.